Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fast skeletal muscle myosin refers to a family of motor proteins predominantly expressed in **fast-twitch** fibers (**type II fibers**) within vertebrate **skeletal muscles**. These proteins are responsible for rapid contractions required during activities such as sprinting or sudden movements. Structurally, each molecule consists primarily of two heavy chains—encoded by genes such as *MYH1*, *MYH2*, *MYH4*—and four light chains. The head domain binds actin filaments and hydrolyzes ATP to generate mechanical force through conformational changes known as power strokes[5][7]. This process underlies the sliding filament mechanism central to all striated muscular contraction. Fast-type isoforms differ from their slow counterparts by exhibiting higher ATPase activity and faster crossbridge cycling rates, enabling quick but less fatigue-resistant contractions compared to slow-twitch fibers[4]. In addition to their primary role in movement generation, alterations or mutations affecting these molecules—or their regulatory partners like **fast skeletal myosin-binding protein-C** (*fMyBP-C*)—are implicated in various inherited muscular diseases including distal arthrogryposis and other forms of congenital weakness syndromes[1][3]. Therapeutic interest centers on modulating these proteins' function either directly through small molecules that affect contractility kinetics or indirectly via pathways regulating calcium sensitivity. However, achieving tissue-specific effects without impacting cardiac function remains an ongoing challenge due to structural similarities among different striated-muscle isoforms.
For drugs targeting this molecule or its pathway— – Modulation of actin-myosin interaction kinetics to enhance force production or slow relaxation. – Alteration of calcium sensitivity within the contractile apparatus. – Stabilization or destabilization of crossbridge formation between actin and fast-type myosins.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fast skeletal muscle myosin (None commonly used; sometimes abbreviated as "fast MyHC" (myosin heavy chain) in literature, but no universal abbreviation.).